Cystic Fibrosis Treatment Report

www.CysticFibrosisTreatmentReport.com

MRT5005

Translate Bio Receives FDA Fast Track Designation for MRT5005, an inhaled mRNA therapeutic, for the Treatment of Cystic Fibrosis

https://www.biospace.com/article/releases/translate-bio-receives-fda-fast-track-designation-for-mrt5005-for-the-treatment-of-cystic-fibrosis/

Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis

Feb 26, 2020

— First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 —

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

https://clinicaltrials.gov/ct2/show/NCT03375047?recrs=abdf&type=Intr&cond=Cystic+Fibrosis&lupd_s=03%2F07%2F2019&lupd_d=14

Condition :   Cystic Fibrosis

Interventions :   Drug: MRT5005;   Drug: Normal saline

Sponsor :   Translate Bio, Inc.

Recruiting

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

NCT03375047

Fri, 15 Dec 2017 12:00:00 EST

Last Update Posted: 03/21/19 09:54AM

Back to top